Cross-referencing clinical data
Panax Notoginseng
- Category
- Herb
Nothing to show here, and the reason why.
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Panax Notoginseng has none that clears that bar.
No pairing for Panax Notoginseng has cleared review yet.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
Plays well withEstablished knowledge, not a trial
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Panax Notoginseng + AstragalusA combined extract of the two has been studied together; the design does not separate their contributions
Astragalus and notoginseng saponins are a long-standing formula pairing and have been evaluated as a fixed combined extract rather than as separate arms. That design means any result belongs to the combination, and nothing can be assigned to notoginseng on its own. The pairing is real as formulation practice; the attribution is not available.
Panax Notoginseng + ProbioticsEstablished microbial conversion of ginsenosides to compound K
Protopanaxadiol ginsenosides such as Rb1 are poorly absorbed intact. Colonic bacteria remove sugar units stepwise to yield compound K, which is the species that actually reaches circulation in quantity. People differ several-fold in how efficiently they perform that conversion, and non-converters get much less systemic exposure from the same amount. Whether a specific strain reliably raises conversion in people has not been settled.
Panax Notoginseng + Fish OilEstablished omega-3 pharmacology plus documented effects of notoginseng saponins on platelet function
Notoginseng saponins reduce platelet aggregation in laboratory and animal work, and high-intake EPA and DHA push in the same direction in people. The combined effect on bleeding tendency is the point worth flagging, not a benefit. This is mechanistic overlap, not a tested combination.
Panax Notoginseng + GingerOverlapping effects on platelet aggregation
Both have shown antiplatelet activity in laboratory preparations. Neither has been established as producing a clinically meaningful change at ordinary supplement intakes, and the combination has not been studied in people. Listed for direction only.
Panax Notoginseng + Vitamin K1Established opposing action on haemostasis
Notoginseng is unusual in carrying both a haemostatic constituent, dencichine, and antiplatelet saponins, so its net effect on clotting is not one-directional. Vitamin K1 supports gamma-carboxylation of clotting factors on the opposite side of the ledger. Anyone whose clotting is being managed deliberately has a reason to know both are in the mix and to raise it with their prescriber.
Panax Notoginseng + Black Pepper Extract (BioPerine)Established pharmacology of piperine on intestinal transporters and phase I enzymes
Piperine inhibits P-glycoprotein and CYP3A4, and several ginsenosides are P-glycoprotein substrates. In principle that raises exposure to the saponins that do get absorbed. No human pharmacokinetic study has measured this pairing for notoginseng specifically, so the size and even the reliability of the effect are unknown.
Who should be cautious
Nothing specific on file for Panax Notoginseng. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.The forms it comes in.
Unsteamed rootNative saponin profile dominated by R1, Rb1 and Rg1, plus dencichineFits Traditional raw use, and any application where the native chemistry is the pointTrade-off Absorption of the major saponins depends heavily on the user's gut bacteria, so exposure varies between people from the same amount
Processed rootHeat processing converts polar saponins toward rare ginsenosides including Rg3, Rk1 and Rg5Fits Preparations built around the rare ginsenoside fraction, which is less dependent on microbial conversionTrade-off A different chemical article from the raw root, so evidence generated on raw material does not transfer directly
Standardised total saponin extractEnriched total saponin fraction, typically declared to a combined percentage of R1, Rg1 and Rb1Fits Products needing a defined saponin figure per serving and batch consistencyTrade-off The non-saponin fraction, including dencichine and polysaccharides, is largely stripped out
Leaf and stem materialDifferent saponin distribution from the root, richer in certain protopanaxadiol typesFits Lower-cost material and by-product use, including animal feed applicationsTrade-off Not chemically equivalent to root material, and root evidence should not be applied to it
Pre-converted compound K extractGinsenosides deglycosylated in production by enzymes or microbial culture, delivering compound K directlyFits Users whose gut bacteria convert poorly, where the conversion step is done before ingestionTrade-off Bypasses the natural glycoside profile entirely, and the delivered molecule mix differs from anything the plant produces
What the strongest studies found
The essence, in one line each.
- Participants taking Panax notoginseng before endurance exercise showed improved endurance performance measures compared with the control condition.Randomised trial. Liang MT et al., 2005 (Journal of Strength and Conditioning Research). PMID 15744902 ↗
- Notoginseng saponins reduced markers of diet-induced liver stress in rodents fed a high-fat diet, with the authors proposing lipid-handling mechanisms.Animal study. Li R et al., 2026 (Food Science & Nutrition). PMID 41695106 ↗
- Carbon dots derived from Panax notoginseng reduced kidney injury markers after ischaemia and reperfusion in an animal model.Animal study. Yang M et al., 2026 (Theranostics). PMID 41695479 ↗
- Single-cell multiomics identified vascular cell populations affected in the model, and Panax notoginseng derived vesicles acted on those populations.Animal study. Xia F et al., 2026 (Materials Today Bio). PMID 41560797 ↗
- Stems and leaves of Panax notoginseng altered mRNA expression of TLR signalling pathway components in the animals studied.Animal study. Zhang N et al., 2025 (Genes). PMID 40725434 ↗
- Panax notoginseng processing residue shifted rumen microbial community composition and blood biochemical parameters in the animals studied.Animal study. Wu D et al., 2025 (Animals). PMID 40150317 ↗
- Metagenomic profiling linked rhizosphere microbial community composition and soil properties to the levels of active constituents in the harvested plants.Cohort study. Liang ZW et al., 2026 (Journal of Ginseng Research). PMID 41788574 ↗
These are the studies our verdict leans on, chosen from the 7 we read for Panax Notoginseng. The full linked list is below.
The studies, linked.
9 sources behind our Panax Notoginseng verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialA Non-interventional, Controlled, Open-label, Observational Registry Study to Investigate the Safety and Effectiveness of LUOTAI (Panax Notoginseng) Injectable and Soft Capsules in Patients With Acute Ischemic Stroke in VietnamClinicalTrials.gov ↗364 participants · Completed
- Clinical trialClinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations:A Prospective Randomized Controlled Multi-site Clinical Trial About Fractions-based Herbal Combinations of Clearing Heat and Promoting Blood CirculationClinicalTrials.gov ↗NA · 120 participants · Completed
- Clinical trialA Randomized, Placebo-controlled, Double-blind, Parallel Study to Determine the Effect of Farlong® NotoGinseng™ (Farlong® Ginseng Plus®) on Cholesterol and Blood PressureClinicalTrials.gov ↗PHASE2 · 95 participants · Completed
- Clinical trialClinical Study on the Treatment of Hypertensive Cerebral Hemorrhage With Panax Notoginseng SaponinsClinicalTrials.gov ↗PHASE4 · 90 participants · Completed
- Clinical trialClinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary InterventionClinicalTrials.gov ↗PHASE1 · 60 participants · Completed
- Clinical trialClinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary InterventionClinicalTrials.gov ↗PHASE3 · 400 participants · Not yet recruiting
- Clinical trialHeat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory ActionClinicalTrials.gov ↗NA · 120 participants · Unknown
- Clinical trialThe Effect of Panax Notoginseng Powders on Rheumatic PainClinicalTrials.gov ↗NA · 80 participants · Unknown
- Clinical trialImpact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide in Acute Coronary Syndromes : A Randomized Placebo Controlled TrialClinicalTrials.gov ↗NA · 80 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 12,232 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Panax Notoginseng is, not how risky it is. A report is not proof Panax Notoginseng caused anything. It is a signal of what to watch for, nothing more.
Drug Ineffective
641
Macular Degeneration
589
Constipation
434
Pain
397
Off Label Use
367
Nausea
315
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
